dc.contributor.author | Macinnis, RJ | |
dc.contributor.author | Antoniou, AC | |
dc.contributor.author | Eeles, RA | |
dc.contributor.author | Severi, G | |
dc.contributor.author | Al Olama, AA | |
dc.contributor.author | McGuffog, L | |
dc.contributor.author | Kote-Jarai, Z | |
dc.contributor.author | Guy, M | |
dc.contributor.author | O'Brien, LT | |
dc.contributor.author | Hall, AL | |
dc.contributor.author | Wilkinson, RA | |
dc.contributor.author | Sawyer, E | |
dc.contributor.author | Ardern-Jones, AT | |
dc.contributor.author | Dearnaley, DP | |
dc.contributor.author | Horwich, A | |
dc.contributor.author | Khoo, VS | |
dc.contributor.author | Parker, CC | |
dc.contributor.author | Huddart, RA | |
dc.contributor.author | Van As, N | |
dc.contributor.author | McCredie, MR | |
dc.contributor.author | English, DR | |
dc.contributor.author | Giles, GG | |
dc.contributor.author | Hopper, JL | |
dc.contributor.author | Easton, DF | |
dc.date.accessioned | 2018-06-13T11:02:41Z | |
dc.date.issued | 2011-07-18 | |
dc.identifier.citation | Genetic epidemiology, 2011, 35 (6), pp. 549 - 556 | |
dc.identifier.issn | 0741-0395 | |
dc.identifier.uri | https://repository.icr.ac.uk/handle/internal/1858 | |
dc.identifier.eissn | 1098-2272 | |
dc.identifier.doi | 10.1002/gepi.20605 | |
dc.description.abstract | Genome wide association studies have identified several single nucleotide polymorphisms (SNPs) that are independently associated with small increments in risk of prostate cancer, opening up the possibility for using such variants in risk prediction. Using segregation analysis of population-based samples of 4,390 families of prostate cancer patients from the UK and Australia, and assuming all familial aggregation has genetic causes, we previously found that the best model for the genetic susceptibility to prostate cancer was a mixed model of inheritance that included both a recessive major gene component and a polygenic component (P) that represents the effect of a large number of genetic variants each of small effect, where . Based on published studies of 26 SNPs that are currently known to be associated with prostate cancer, we have extended our model to incorporate these SNPs by decomposing the polygenic component into two parts: a polygenic component due to the known susceptibility SNPs, , and the residual polygenic component due to the postulated but as yet unknown genetic variants, . The resulting algorithm can be used for predicting the probability of developing prostate cancer in the future based on both SNP profiles and explicit family history information. This approach can be applied to other diseases for which population-based family data and established risk variants exist. | |
dc.format | Print-Electronic | |
dc.format.extent | 549 - 556 | |
dc.language | eng | |
dc.language.iso | eng | |
dc.publisher | WILEY | |
dc.rights.uri | https://www.rioxx.net/licenses/all-rights-reserved | |
dc.subject | Humans | |
dc.subject | Prostatic Neoplasms | |
dc.subject | Models, Statistical | |
dc.subject | Probability | |
dc.subject | Risk | |
dc.subject | Polymorphism, Single Nucleotide | |
dc.subject | Algorithms | |
dc.subject | Models, Genetic | |
dc.subject | Adult | |
dc.subject | Aged | |
dc.subject | Middle Aged | |
dc.subject | Australia | |
dc.subject | Male | |
dc.subject | Genetic Variation | |
dc.subject | Genome-Wide Association Study | |
dc.subject | Molecular Epidemiology | |
dc.subject | United Kingdom | |
dc.title | A risk prediction algorithm based on family history and common genetic variants: application to prostate cancer with potential clinical impact. | |
dc.type | Journal Article | |
dcterms.dateAccepted | 2011-05-31 | |
rioxxterms.versionofrecord | 10.1002/gepi.20605 | |
rioxxterms.licenseref.uri | https://www.rioxx.net/licenses/all-rights-reserved | |
rioxxterms.licenseref.startdate | 2011-09 | |
rioxxterms.type | Journal Article/Review | |
dc.relation.isPartOf | Genetic epidemiology | |
pubs.issue | 6 | |
pubs.notes | Not known | |
pubs.organisational-group | /ICR | |
pubs.organisational-group | /ICR/Primary Group | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Closed research teams | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Closed research teams/Clinical Academic Radiotherapy (Dearnaley) | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Genetics and Epidemiology | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Genetics and Epidemiology/Oncogenetics | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Radiotherapy and Imaging | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Radiotherapy and Imaging/Clinical Academic Radiotherapy (Huddart) | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Radiotherapy and Imaging/Oncogenetics | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Radiotherapy and Imaging/Stereotactic and Precision Body Radiotherapy | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Radiotherapy and Imaging/Stereotactic and Precision Body Radiotherapy/Stereotactic and Precision Body Radiotherapy (hon.) | |
pubs.organisational-group | /ICR/Primary Group/Royal Marsden Clinical Units | |
pubs.organisational-group | /ICR | |
pubs.organisational-group | /ICR/Primary Group | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Closed research teams | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Closed research teams/Clinical Academic Radiotherapy (Dearnaley) | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Genetics and Epidemiology | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Genetics and Epidemiology/Oncogenetics | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Radiotherapy and Imaging | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Radiotherapy and Imaging/Clinical Academic Radiotherapy (Huddart) | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Radiotherapy and Imaging/Oncogenetics | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Radiotherapy and Imaging/Stereotactic and Precision Body Radiotherapy | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Radiotherapy and Imaging/Stereotactic and Precision Body Radiotherapy/Stereotactic and Precision Body Radiotherapy (hon.) | |
pubs.organisational-group | /ICR/Primary Group/Royal Marsden Clinical Units | |
pubs.publication-status | Published | |
pubs.volume | 35 | |
pubs.embargo.terms | Not known | |
icr.researchteam | Clinical Academic Radiotherapy (Dearnaley) | |
icr.researchteam | Clinical Academic Radiotherapy (Huddart) | |
icr.researchteam | Oncogenetics | |
icr.researchteam | Stereotactic and Precision Body Radiotherapy | |
dc.contributor.icrauthor | Eeles, Rosalind | |
dc.contributor.icrauthor | Kote-Jarai, Zsofia | |
dc.contributor.icrauthor | Dearnaley, David | |
dc.contributor.icrauthor | Horwich, Alan | |
dc.contributor.icrauthor | Huddart, Robert | |